Kratom News logo
DEA 7-OH notice of intent graphic: Federal Register docket DEA-1570, publication Oct. 14, 2026, temporary scheduling order no earlier than Nov. 13, 2026
DEA Docket No. DEA-1570, Federal Register document 2026-20943, filed for public inspection Oct. 9, 2026.

Headlines over the weekend said the federal 7-OH ban takes effect Nov. 13. The document those headlines describe says something narrower. What the Drug Enforcement Administration filed on Oct. 9 is a 7-OH notice of intent, and the Federal Register itself classifies it as a proposed amendment rather than a final order. Nothing about the legal status of 7-hydroxymitragynine changes on the day it publishes, and nothing is automatic on Nov. 13 either.

The distinction is not a technicality. It sets when retailers have to pull product, what the American Kratom Association actually settled, and which parts of the federal picture stay exactly as they are in the meantime.

THE FILING BY THE NUMBERS
Oct. 14
Scheduled Federal Register publication date
30 days
Statutory wait before any order may issue
1 mg/g
Concentration prong of the new threshold
100 to 1
Mitragynine ratio prong of the same test

📋 What the 7-OH notice of intent actually is

The action line on the first page reads “Proposed amendment; notice of intent.” It is issued under the temporary scheduling provisions of 21 U.S.C. 811(h), which require the DEA to publish notice of its intent and the grounds for it before it may issue a temporary scheduling order. The notice says the Administrator “intends to issue a temporary scheduling order,” and that the order “will not be issued before” 30 days after publication.

That sequence is why the Nov. 13 date keeps appearing. It is 30 days past the Oct. 14 publication date, which makes it the earliest the DEA could act, not a date the agency has committed to. The notice adds that the Administrator intends to issue the order “as soon as possible after the expiration of 30 days,” so the gap is likely to be short. It is still a gap.

Timeline of the DEA 7-OH notice of intent: Oct. 8, 2026 HHS letter, Oct. 9 public inspection filing, Oct. 14 Federal Register publication, Nov. 13 earliest temporary scheduling order
The statutory sequence under 21 U.S.C. 811(h).

⏱️ Four dates that drive everything

On Oct. 8, HHS Assistant Secretary for Health Admiral Brian Christine, M.D., sent the DEA a letter recommending a single combined threshold covering both 7-hydroxymitragynine and mitragynine pseudoindoxyl. The DEA filed the resulting notice for public inspection the next day. Publication is set for Oct. 14, and the 30-day clock runs from there.

The Oct. 8 recommendation replaced an earlier and lower threshold that HHS had provided in July 2025. That older figure drove the July 7 notice of intent on 7-OH, which the DEA says it is withdrawing in a companion document in the same Federal Register issue. The practical effect is that the July proceeding is being replaced wholesale rather than amended.

Announcing the recommendation, HHS Secretary Robert F. Kennedy, Jr. said the agencies were “drawing a clear line between natural kratom and dangerous, enhanced opioid products.”

⚖️ What stays in force in the meantime

This is the part most of the weekend coverage skipped. The DEA’s Aug. 26 temporary order placing mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I is still in effect, and that order carries no threshold at all. The new notice says so plainly: the August order “remains in effect until either it expires or the new temporary order is published and the previous order is withdrawn, whichever occurs first.”

So for now, mitragynine pseudoindoxyl is a Schedule I substance at any detectable amount under federal law, and the more permissive combined threshold does not exist yet. Relief, if it comes, arrives with the temporary order, not with the notice announcing it.

“Neither HHS nor DEA has made a finding that these substances are safe to use at below-threshold levels.” DEA, notice of intent, Docket No. DEA-1570

🧪 The threshold is a two-prong test, not a single number

The HHS language quoted in the notice controls either substance alone or their combined amount when the product is above a concentration of 1 mg per gram for solids, powders and capsules, or 1 mg per milliliter for liquids, or when the mass of mitragynine divided by the mass of 7-OH, MGPI, or both combined, is less than 100.

Either prong is enough. A product can sit under 1 mg per gram and still be scheduled because its alkaloid ratio is out of line with natural leaf. We walked through the arithmetic in our piece on the 1 mg/g and 100-to-1 ratio test. For anyone stocking shelves, a figure for total 7-OH is not enough on its own, because the ratio prong needs a mitragynine number beside it.

🏛️ The courthouse door is mostly closed on this one

The notice is blunt about review: “Temporary scheduling orders are not subject to judicial review,” citing 21 U.S.C. 811(h)(6). It also states that the notice-and-comment requirements of the Administrative Procedure Act do not apply to a notice of intent, because section 811(h) sets out its own procedure. There is no comment period attached to this filing.

That reframes the litigation news. The American Kratom Association sued the DOJ, the DEA and Administrator Terrance C. Cole in the U.S. District Court for the District of Columbia on Sept. 2, docket 1:26-cv-02997. As we reported then, the suit did not try to strike the MGPI order down; it asked the court to confirm the order does not reach traditional leaf carrying trace amounts. AKA lobbyist Mac Haddow says the parties agreed to dismiss, conditioned on the DEA publishing the schedule it submitted to the court. The case closes when the notice publishes, and not before.

The DEA does say it intends to pursue permanent scheduling through formal rulemaking under 21 U.S.C. 811(a), including a full scientific and medical evaluation from HHS. Final decisions from that process are reviewable in court. That is where the thresholds get genuinely tested, and it is years from resolution.

🌐 What retailers and consumers should take from it

Not everyone is satisfied. The 7-HOPE Alliance, which represents 7-OH product interests, notes that the filing is a notice of intent rather than a scheduling order and treats that as room to keep negotiating. Read against the statute, that is accurate about the document and optimistic about the outcome, since the agency controls the timing and the courts are largely unavailable.

For sellers, the sensible posture is to treat Nov. 13 as a deadline rather than a forecast, and to remember that MGPI is already controlled without a threshold today. For consumers, the safety record behind this action deserves attention regardless of how the procedure resolves. FDA’s review found 7-OH considerably more potent than morphine in preclinical work, and identified evidence of meaningful risk of opioid-like physical dependence and withdrawal. Kratom in any form, including plain leaf, carries a real risk of physical dependence with regular use, and stopping abruptly after sustained use can produce withdrawal. Anyone currently using concentrated 7-OH products should talk with a clinician rather than stopping cold on a regulatory deadline.

We track which sellers publish usable alkaloid data on our Kratom Vendors directory. The honest state of play on Oct. 11 is simple enough: the federal threshold everyone is planning around is not law yet, the narrower August order that is law has no threshold in it, and the first date that can change either of those is Oct. 14.

❓ Frequently asked questions

Is the 7-OH ban in effect right now?

Not the threshold-based one. The Oct. 9 filing is a notice of intent scheduled to publish Oct. 14, 2026, and the DEA cannot issue the temporary scheduling order before 30 days have passed, which puts the earliest date at Nov. 13, 2026. Separately, the DEA’s Aug. 26, 2026 temporary order placing mitragynine pseudoindoxyl in Schedule I without any threshold is already in effect.

What is the new threshold the DEA proposed?

Schedule I control applies when 7-hydroxymitragynine alone, mitragynine pseudoindoxyl alone, or their combined amount is above 1 mg per gram in solids or 1 mg per milliliter in liquids, or when the mass of mitragynine divided by the mass of those compounds is less than 100. Either prong is sufficient on its own.

Does this 7-OH notice of intent ban natural leaf kratom?

The stated intent is the opposite. HHS and the DEA describe the threshold as a line meant to separate concentrated and chemically altered products from botanical leaf, which can carry trace amounts of both compounds. The DEA also states that it has made no finding that these substances are safe below the threshold, and that it still regards kratom and its major alkaloids as drugs of concern.

Can the threshold be challenged in court?

Not the temporary order. The notice cites 21 U.S.C. 811(h)(6) for the rule that temporary scheduling orders are not subject to judicial review, and says the Administrative Procedure Act’s notice-and-comment requirements do not apply. The DEA intends to pursue permanent scheduling under 21 U.S.C. 811(a), and final decisions from that process are reviewable.

What happened to the American Kratom Association lawsuit?

AKA filed American Kratom Association v. DEA in the U.S. District Court for the District of Columbia on Sept. 2, 2026, docket 1:26-cv-02997, seeking confirmation that the MGPI order does not reach traditional leaf kratom. AKA says the parties agreed to dismiss, conditioned on the DEA publishing the schedule it submitted to the court. The dismissal therefore depends on the Oct. 14 publication going through.

📚 Sources

Not medical advice. This article is news reporting about law and regulation. It is not medical advice and makes no claim that kratom or any kratom-derived compound treats, cures or prevents any condition. Kratom carries a risk of physical dependence and withdrawal with regular use. Talk with a qualified healthcare professional before starting, changing or stopping any product, and seek professional help if you are concerned about dependence.